droperidol is also often used as a sedative in intensive care treatment discovered at janssen pharmaceutica in 1961 droperidol is a butyrophenone which acts a potent d dopamine receptor antagonist with some histamine and serotonin antagonist activity it has a central antiemetic action and effectively prevents postoperative nausea and vomiting in adults using doses as low as 0 625 mg for treatment of nausea and vomiting droperidol and ondansetron are equally effective droperidol is more effective than metoclopramide it has also been used as an antipsychotic in doses ranging from 5 to 10 mg given as an intramuscular injection generally in cases of severe agitation in a psychotic patient who is refusing oral medication its use in intramuscular sedation has been replaced by intramuscular preparations of haloperidol midazolam clonazepam and olanzapine some practitioners recommend the use of 0 5 mg to 1 mg intravenously for the treatment of vertigo in an otherwise healthy elderly patients who have not responded to epley maneuvers in 2001 the fda changed the labeling requirements for droperidol injection to include a black box warning citing concerns of qt prolongation and torsades de pointes the evidence for this is disputed with 9 reported cases of torsades